Taking serious note of the delay in payment, the court said, “A superannuated employee has a right to retiral benefits and it is not a bounty that is expected from the employer. These ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.